Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury.

Arun SamiduraiFadi N SalloumDavid DurrantOlga B ChernovaRakesh C KukrejaAnindita Das

Published in: British journal of pharmacology (2017)

Our studies indicate that chronic treatment with Rapatar improves metabolic status and cardiac function with a reduction of infarct size following myocardial I/R injury in diabetic mice.

Keyphrases

acute myocardial infarction
type diabetes
heart failure
drug delivery
left ventricular
atrial fibrillation
acute coronary syndrome
wound healing
blood brain barrier